In the present study, we have shown that a combination treatment using ERK1/2 inhibitor AZD0364 and PI3K inhibitor ZSTK474 enhanced anticancer effects in leukemia cells by reducing cell viability, and inducing ROS production and apoptosis. Here, MAPK3 is linked to leukemia.